215529-50-3

Upstream product

• 215530-54-4 4-(diphenylmethoxy)-1-piperidinepropanol 
• 215530-66-8 tert-butyl 2-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropionate 
• 215530-63-5 ethyl 2-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropionate 
• 215530-65-7 2-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2-methylpropionic acid 
• 58258-01-8 4-diphenylmethoxypiperidine 
• 63891-88-3 ethyl 4-bromo-2,2-dimethyl-3-oxobutanoate 
• 215529-48-9 tert-Butyl 2-[6-[3-[4-(diphenylmethoxy)piperidino]-propoxy]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropionate 

Relevant academic research and scientific papers

Synthesis of eosinophil infiltration inhibitors with antihistaminic activity.

A series of [1, 2, 4]triazolo[1, 5-b]pyridazines (5) and imidazo[1, 2-b]pyridazines (6) having cyclic amines was synthesized and evaluated for antihistaminic activity and inhibitory effect on eosinophil infiltration. When a piperidine or a piperazine containing a benzhydryl group and a suitable spacer was incorporated at the 6-position, the fused pyridazines were found to exhibit both antihistaminic activity and an inhibitory effect on eosinophil chemotaxis. Above all, 6a showed potent antihistaminic activity, but little blockade of central H(1) receptors in contrast with its complete blockade of peripheral H(1) receptors as determined by an ex vivo binding assay. Furthermore, 6a inhibited eosinophil infiltration of the skin caused by a topical antigen challenge in sensitized guinea pigs, while an antihistamine terfenadine was not effective. After the pharmacokinetic study, 6a was found to be rapidly hydrolyzed to 6o, which was also orally active. Compound 6o, 2-[6-[[3-[4-(diphenylmethoxy)piperidino]propyl]amino]imidazo[1, 2-b]pyridazin-2-yl]-2-methylpropionic acid dihydrate (TAK-427), having both antihistaminic and antiinflammatory activity, is currently undergoing clinical trials as a therapeutic agent for atopic dermatitis and allergic rhinitis.

NASAL DROPS CONTAINING FUSED PYRIDAZINE DERIVATIVES

A nose drop containing the compound (I) represented by the formula wherein Ar1 and Ar2 are each an aromatic group, Ar1 and Ar2 optionally form a condensed cyclic group together with the adjacent carbon atom, ring B is a nitrogen-containing heterocycle, X and Y are each a bond, an oxygen atom or S(O)p (p is 0 to 2), NR4 (R4 is H or a lower alkyl group) or a divalent linear lower hydrocarbon group optionally having substituents and containing 1 to 3 heteroatoms, A is N or CR7 (R7 is H, a halogen atom, a hydrocarbon group, an acyl group or a hydroxy group optionally having substituents), R1, R2 and R3 are each H, a halogen atom, a hydrocarbon group, an acyl group or a hydroxy group optionally having substituents, and R8 is H, a hydroxy group optionally substituted by a lower alkyl group or a carboxyl group, provided that the nitrogen-containing heterocycle represented by ring B is not a heterocycle represented by the formula wherein n is 0 - 1, or a salt thereof or a prodrug thereof, exhibits a superior prophylactic or therapeutic effect on allergic rhinitis and the like.